Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 9/20 | 0.48 |
| ▸ | TACR1 | P25103 | 6/20 | 0.46 |
| ▸ | TACR3 | P29371 | 5/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | CCR5 | P51681 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4631196 | 0.86 | TACR2 (0.51) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| SCHEMBL14028100 | 0.86 | SLC6A4 (0.42) | PKM | |
| SCHEMBL4630712 | 0.85 | TACR2 (0.59) | TACR2CYP3A4CYP2D6CHRM2CHRM3 | |
| SCHEMBL4942393 | 0.85 | P2RX7 (0.39) | TACR2 | |
| SCHEMBL4630890 | 0.84 | TACR2 (0.49) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| SCHEMBL6999695 | 0.84 | TACR2 (0.49) | TACR2TACR1TACR3 | |
| SCHEMBL4631761 | 0.82 | TACR2 (0.49) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| SCHEMBL4941176 | 0.82 | KDM4E (0.43) | TACR2 | |
| SCHEMBL4630697 | 0.81 | TACR2 (0.50) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| SCHEMBL6947952 | 0.81 | TACR2 (0.61) | TACR2TACR1TACR3CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080261976-A1 | NOVEL PIPERIDINECARBOXAMIDE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SANOFI-AVENTIS (FR) | 2008-10-23 | — | — | US | disclosed |
| EP-1395582-B1 | NOVEL PIPERIDINECARBOXAMIDE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SANOFI AVENTIS (FR) | 2005-05-04 | — | — | EP | disclosed |
| US-20040180890-A1 | Novel piperidinecarboxamide derivatives, method for preparing same and pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2004-09-16 | — | — | US | disclosed |
| EP-1395582-A1 | NOVEL PIPERIDINECARBOXAMIDE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | Sanofi-Aventis (FR) | 2004-03-10 | — | — | EP | disclosed |
| WO-2002094821-A1 | NOVEL PIPERIDINECARBOXAMIDE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SANOFI-SYNTHELABO (FR) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261976-A1 | NOVEL PIPERIDINECARBOXAMIDE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | TACR2, TACR1, KIT | TACR2 1/4885TACR1 2/4885TACR3 73/4885 |
| US-20040180890-A1 | Novel piperidinecarboxamide derivatives, method for preparing same and pharmaceutical compositions containing same | KIT, TACR2, P2RX3 | TACR2 2/4885TACR1 4/4885TACR3 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.